These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 20651400

  • 1. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors.
    Braggio E, Braggio Dde A, Small IA, Lopes LF, Valadão M, Gouveia ME, Moreira Ados S, Linhares E, Romano S, Bacchi CE, Renault IZ, Guimarães DP, Ferreira CG.
    Anticancer Res; 2010 Jun; 30(6):2407-14. PubMed ID: 20651400
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
    Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom LG, Nilsson B.
    Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
    [Abstract] [Full Text] [Related]

  • 3. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
    Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro J, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martínez J, De Juan A, Laínez N, Losa F, Alija V, Escudero P, Casado A, García P, Blanco R, Buesa JM, Spanish Group for Sarcoma Research.
    J Clin Oncol; 2005 Sep 01; 23(25):6190-8. PubMed ID: 16135486
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
    Tzen CY, Wang MN, Mau BL.
    Eur J Surg Oncol; 2008 May 01; 34(5):563-8. PubMed ID: 17532173
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
    Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR.
    Cancer; 2008 Feb 01; 112(3):608-15. PubMed ID: 18076015
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine kinase mutations in gastrointestinal stromal tumors in a nation-wide study in Iceland.
    Tryggvason G, Hilmarsdottir B, Gunnarsson GH, Jónsson JJ, Jónasson JG, Magnússon MK.
    APMIS; 2010 Sep 01; 118(9):648-56. PubMed ID: 20718716
    [Abstract] [Full Text] [Related]

  • 10. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
    Keun Park C, Lee EJ, Kim M, Lim HY, Choi DI, Noh JH, Sohn TS, Kim S, Kim MJ, Lee HK, Kim KM.
    Ann Surg; 2008 Jun 01; 247(6):1011-8. PubMed ID: 18520229
    [Abstract] [Full Text] [Related]

  • 11. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S, Chen LR, Wang HJ, Chen SZ.
    Hepatogastroenterology; 2007 Dec 01; 54(80):2285-90. PubMed ID: 18265649
    [Abstract] [Full Text] [Related]

  • 12. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, Corless CL, Heinrich MC, Fletcher JA.
    Cancer Res; 2007 Oct 01; 67(19):9084-8. PubMed ID: 17909012
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar 01; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P.
    Clin Cancer Res; 2008 Jul 15; 14(14):4550-5. PubMed ID: 18628470
    [Abstract] [Full Text] [Related]

  • 16. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort.
    Battochio A, Mohammed S, Winthrop D, Lefresne S, Mulder K, Chu Q, O'Hara C, Lai R.
    Am J Clin Pathol; 2010 Jan 15; 133(1):149-55. PubMed ID: 20023271
    [Abstract] [Full Text] [Related]

  • 17. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series.
    Gomes AL, Gouveia A, Capelinha AF, de la Cruz D, Silva P, Reis RM, Pimenta A, Lopes JM.
    J Clin Pathol; 2008 Feb 15; 61(2):203-8. PubMed ID: 17827398
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J, Miettinen M.
    Histopathology; 2008 Sep 15; 53(3):245-66. PubMed ID: 18312355
    [Abstract] [Full Text] [Related]

  • 19. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
    Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechtersheimer G.
    J Clin Pathol; 2005 Jun 15; 58(6):634-9. PubMed ID: 15917417
    [Abstract] [Full Text] [Related]

  • 20. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    Acta Oncol; 2012 Apr 15; 51(4):528-36. PubMed ID: 22150077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.